The Tepezza lawsuit payout question has a short answer for now: as of November 2026, no public settlement or jury verdict has paid any plaintiff in the federal Tepezza hearing-loss cases. Tepezza (teprotumumab-trbw) treats thyroid eye disease. Horizon Therapeutics developed it, and Amgen now owns Horizon. Hundreds of patients claim the drug caused permanent hearing loss or tinnitus and that the original label did not warn them well enough. The company denies these claims. The federal cases sit in one multidistrict litigation (MDL) in Chicago. This guide explains where that case stands, what has happened in court, how the drug label changed, and the general factors that shape payouts in drug injury cases. It does not give legal advice. A licensed attorney can review any individual situation.
| Quick Fact | Details |
|---|---|
| Drug | Tepezza (teprotumumab-trbw), an IV infusion for thyroid eye disease |
| Maker | Horizon Therapeutics, now part of Amgen |
| Main allegation | Failure to warn about hearing loss and tinnitus |
| Federal case | In re: Tepezza Marketing, Sales Practices, and Products Liability Litigation, MDL No. 3079 |
| Court | U.S. District Court, Northern District of Illinois |
| Judge | U.S. District Judge Thomas M. Durkin |
| Pending cases | 277 (JPML report dated August 3, 2026) |
| Payouts | None publicly announced as of November 2026 |
Has Anyone Received a Tepezza Lawsuit Payout?
No public payout exists as of November 2026. No jury has returned a verdict for a plaintiff, and neither side has announced a global settlement.
In October 2025, the court struck all deadlines tied to the upcoming bellwether trials after an off-the-record talk with counsel. Legal trade press reported that this move led to speculation about a possible global settlement covering more than 270 cases. That speculation has not been confirmed in any public court filing or company statement we could find. Any figure you see online that claims to be an “average Tepezza settlement” is an estimate, not a confirmed amount.
What Is MDL No. 3079?
MDL No. 3079 is the federal multidistrict litigation that groups the Tepezza hearing-loss lawsuits before one judge. The Judicial Panel on Multidistrict Litigation (JPML) created it on June 2, 2023.
The JPML’s transfer order sent the cases to Judge Thomas M. Durkin in the Northern District of Illinois. At the time, 18 actions were listed for transfer, and the order noted 37 cases pending across eight districts. An MDL is not the same thing as a class action. Each plaintiff keeps an individual case, but the cases share pretrial steps such as discovery and expert rulings. You can read more about how group cases differ in our guide on what a class action lawsuit is.
By the JPML’s August 3, 2026 report, 277 actions were pending in the MDL, and 287 had been filed in total over its life.
What Do the Plaintiffs Allege?
Plaintiffs allege that Horizon knew or should have known that Tepezza could cause serious and sometimes permanent hearing damage, and that the label did not warn clearly enough. These are allegations, not proven facts.
The complaints point to clinical data. According to the plaintiffs, a later study reported a much higher rate of hearing problems than the early trials suggested, and that information could have supported a stronger label sooner. Horizon has argued that federal law preempts many of these claims because the FDA approved the label.
On January 10, 2025, Judge Durkin ruled on motions to dismiss in several bellwether cases. He let the failure-to-warn claims move forward at that stage. He dismissed the design-defect claims with prejudice. He split the fraud claims, dismissing some and allowing label-omission theories to continue. In October 2024, the court had dismissed one bellwether case on choice-of-law grounds under a former Michigan statute that shielded makers of FDA-approved drugs.
Bellwether Trial Schedule
The bellwether trial dates have moved several times, and as of November 2026 we could not confirm that any Tepezza trial has reached a verdict.
In February 2025, the court narrowed a pool of 12 bellwether cases to four. The first trial was set for April 2026, then moved to June 8, 2026. In August 2025, an order reset the schedule to August 3, 2026, September 28, 2026, November 30, 2026, and February 1, 2027. On October 1, 2025, the court struck all bellwether trial deadlines. Some online sources claim a trial began in August 2026, but we found no court record or major news report confirming it. Readers should check the MDL docket for the current calendar.
| Date | Event |
|---|---|
| January 21, 2020 | FDA approves Tepezza for thyroid eye disease |
| June 2, 2023 | JPML creates MDL No. 3079 before Judge Durkin |
| July 2023 | Label updated with a warning on severe hearing impairment |
| October 6, 2023 | Amgen completes its purchase of Horizon |
| October 2024 | One bellwether case dismissed under former Michigan law |
| January 10, 2025 | Ruling on motions to dismiss in bellwether cases |
| February 2025 | Court picks four bellwether trial cases |
| August 2025 | Trials reset to start August 3, 2026 |
| October 1, 2025 | Court strikes all bellwether trial deadlines |
| August 3, 2026 | JPML reports 277 pending cases |
| November 2026 | No public verdict or settlement |
The FDA Label Change on Hearing Impairment
In July 2023, Tepezza’s prescribing information added a new warning stating the drug may cause severe hearing impairment, including hearing loss that in some cases may be permanent.
The updated label lists hearing impairment under Warnings and Precautions. It tells doctors to check patients’ hearing before, during, and after treatment and to weigh benefits against risks. The current label is available on the National Library of Medicine’s DailyMed. Plaintiffs argue this warning came too late for people treated before the change. The timing of the label update is central to the failure-to-warn claims.
What Affects Payouts in Similar Drug Cases?
These are general factors that often shape outcomes in pharmaceutical injury cases. They are not predictions for Tepezza, and no Tepezza amounts have been set.
| General Factor | Why It Can Matter |
|---|---|
| Severity of injury | Permanent hearing loss is usually treated differently from temporary symptoms |
| Medical proof | Hearing tests before and after treatment can help show what changed |
| Treatment date | Use before or after a label change can affect warning claims |
| State law | Each plaintiff’s home state rules can limit or allow certain claims |
| Expert rulings | Courts decide which causation experts juries may hear |
| Bellwether results | Early verdicts often guide later settlement talks |
| Settlement terms | Global deals often use point systems and set fees and liens |
For a plain overview of how group lawsuits work, see our class action lawsuit definition. To follow other mass cases, browse our class actions coverage.
Conclusion
As of November 2026, there is no confirmed Tepezza payout. The MDL in Chicago holds about 277 pending cases. The court cleared the way for failure-to-warn claims but dismissed design-defect claims. The bellwether trial schedule was struck in October 2025, and no verdict or settlement has been made public. Anyone with questions about a possible claim, including filing deadlines, should speak with a licensed attorney.
Frequently Asked Questions
Is there a Tepezza settlement?
No global settlement had been publicly announced as of November 2026. Reports of a possible deal remain unconfirmed.
How much is a Tepezza case worth?
No official amounts exist. Value in drug cases generally depends on injury severity, proof, state law, and trial results.
Who is the judge in the Tepezza MDL?
U.S. District Judge Thomas M. Durkin of the Northern District of Illinois oversees MDL No. 3079.
How many Tepezza lawsuits are pending?
The JPML listed 277 pending actions in its August 3, 2026 report. Numbers change as cases are filed or dismissed.
When did the Tepezza label add a hearing warning?
The prescribing information added a severe hearing impairment warning in July 2023.
Is the Tepezza lawsuit a class action?
No. It is a multidistrict litigation, where each plaintiff keeps an individual case.
Sources
Judicial Panel on Multidistrict Litigation, MDL No. 3079 Transfer Order (June 2, 2023). Judicial Panel on Multidistrict Litigation, Pending MDL Dockets by Actions Pending (August 3, 2026). U.S. District Court for the Northern District of Illinois, opinions in Chryssos v. Horizon Therapeutics USA, Inc. and Pledger v. Horizon Therapeutics USA, Inc. (January 10, 2025). Bloomberg Law, report on bellwether dismissal (October 28, 2024). HarrisMartin Publishing, MDL reports (October 2025 and January 2026). Tepezza prescribing information, National Library of Medicine DailyMed. Eyes On Eyecare, report on the July 2023 label update.
